TABLE 2.
Effect on Follow-up HbA1c for Patients with Type 2 Diabetes and Baseline HbA1c ≥ 7.0% Treated in a Pharmacist-Coordinated DCCM Program Versus Comparison Patients (Ordinary Least Squares Regression Analyses)
| Variables | Model 1: Adjustment for Baseline HbA1c | Model 2: Adjustment for All Controls | Model 3: Adjustment for All Controls Plus Propensity Score as Covariate | Model 4: Adjustment for All Controls Plus Propensity Score Quintile Regression | ||||
|---|---|---|---|---|---|---|---|---|
| Coefficient (95% CI) | P Value | Coefficient (95% CI) | P Value | Coefficient (95% CI) | P Value | Coefficient (95% CI) | P Value | |
| DCCM vs. comparison patients | -0.212 (-0.401, -0.023) | 0.028 | -0.440 (-0.635, -0.245) | < 0.001 | -0.442 (-0.641, -0.243) | < 0.001 | -0.437 (-0.637, -0.238) | <0.001 |
| Baseline HbA1c (per %) | 0.532 (0.476, 0.588) | < 0.001 | 0.502 (0.449, 0.554) | < 0.001 | 0.495 (0.325, 0.665) | < 0.001 | 0.493 (0.375, 0.611) | < 0.001 |
| Propensity score | ||||||||
| Covariate | 0.071 (-1.613, 1.755) | 0.934 | ||||||
| Quintile 2 (reference 1) | 0.005 (-0.251, 0.262) | 0.967 | ||||||
| Quintile 3 | 0.083 (-0.361, 0.527) | 0.713 | ||||||
| Quintile 4 | -0.008 (-0.636, 0.619) | 0.979 | ||||||
| Quintile 5 | 0.098 (-0.821, 1.016) | 0.835 | ||||||
| Constant | 3.507 (3.064, 3.951) | < 0.001 | 4.713 (4.054, 5.372) | < 0.001 | 4.746 (3.717, 5.775) | < 0.001 | 4.762 (3.838, 5.686) | < 0.001 |
Note: Models 2, 3, and 4 were controlled for age, prescription orders for antidiabetic agents the year prior to index date, number of antidiabetic classes prescribed prior to index date, prevalence of prior comorbidities, outpatient charges for 6 months prior to index date, and the number of community clinic visits for 6 months prior to index date.
CI = confidence interval; DCCM = diabetes collaborative care management; HbA1c = hemoglobin A1c.